SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Revance Therapeutics, Inc. – ‘10-K’ for 12/31/23 – ‘EX-97.1’

On:  Wednesday, 2/28/24, at 4:33pm ET   ·   For:  12/31/23   ·   Accession #:  1479290-24-38   ·   File #:  1-36297

Previous ‘10-K’:  ‘10-K’ on 2/28/23 for 12/31/22   ·   Latest ‘10-K’:  This Filing   ·   39 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/28/24  Revance Therapeutics, Inc.        10-K       12/31/23  110:12M

Annual Report   —   Form 10-K   —   SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   2.67M 
 2: EX-4.4      Instrument Defining the Rights of Security Holders  HTML     48K 
 3: EX-10.32    Material Contract                                   HTML     30K 
 4: EX-21.1     Subsidiaries List                                   HTML     28K 
 5: EX-23.1     Consent of Expert or Counsel                        HTML     28K 
10: EX-97.1     Clawback Policy re: Recovery of Erroneously         HTML     50K 
                Awarded Compensation                                             
 6: EX-31.1     Certification -- §302 - SOA'02                      HTML     33K 
 7: EX-31.2     Certification -- §302 - SOA'02                      HTML     33K 
 8: EX-32.1     Certification -- §906 - SOA'02                      HTML     31K 
 9: EX-32.2     Certification -- §906 - SOA'02                      HTML     31K 
16: R1          Cover                                               HTML     95K 
17: R2          Audit Information                                   HTML     34K 
18: R3          Consolidated Balance Sheets                         HTML    150K 
19: R4          Consolidated Balance Sheets (Parenthetical)         HTML     49K 
20: R5          Consolidated Statements of Operations and           HTML    126K 
                Comprehensive Loss                                               
21: R6          Consolidated Statements of Stockholders' Equity     HTML    122K 
                (Deficit)                                                        
22: R7          Consolidated Statements of Cash Flows               HTML    134K 
23: R8          The Company                                         HTML     39K 
24: R9          Summary of Significant Accounting Policies          HTML     91K 
25: R10         Revenue                                             HTML    112K 
26: R11         Restructuring                                       HTML     44K 
27: R12         Cash Equivalents and Short-Term Investments         HTML     69K 
28: R13         Goodwill and Intangible Assets, net                 HTML     98K 
29: R14         Inventories                                         HTML     37K 
30: R15         Accruals and other current liabilities              HTML     44K 
31: R16         Leases                                              HTML     93K 
32: R17         Debt                                                HTML     64K 
33: R18         Stock-based Compensation                            HTML    115K 
34: R19         Stockholders' Equity                                HTML     48K 
35: R20         Fair Value Measurement                              HTML     64K 
36: R21         Income Taxes                                        HTML    101K 
37: R22         Commitments and Contingencies                       HTML     44K 
38: R23         Segment Information                                 HTML     60K 
39: R24         Subsequent Event                                    HTML     31K 
40: R25         Pay vs Performance Disclosure                       HTML     41K 
41: R26         Insider Trading Arrangements                        HTML     35K 
42: R27         Summary of Significant Accounting Policies          HTML    140K 
                (Policies)                                                       
43: R28         Summary of Significant Accounting Policies          HTML     39K 
                (Tables)                                                         
44: R29         Revenue (Tables)                                    HTML    102K 
45: R30         Restructuring (Tables)                              HTML     43K 
46: R31         Cash Equivalents and Short-Term Investments         HTML     70K 
                (Tables)                                                         
47: R32         Goodwill and Intangible Assets, net (Tables)        HTML     99K 
48: R33         Inventories (Tables)                                HTML     38K 
49: R34         Accruals and other current liabilities (Tables)     HTML     43K 
50: R35         Leases (Tables)                                     HTML     87K 
51: R36         Debt (Tables)                                       HTML     50K 
52: R37         Stock-based Compensation (Tables)                   HTML    108K 
53: R38         Stockholders' Equity (Tables)                       HTML     39K 
54: R39         Fair Value Measurement (Tables)                     HTML     62K 
55: R40         Income Taxes (Tables)                               HTML     99K 
56: R41         Segment Information (Tables)                        HTML     54K 
57: R42         The Company (Details)                               HTML     61K 
58: R43         Summary of Significant Accounting Policies -        HTML     69K 
                Narrative (Details)                                              
59: R44         Summary of Significant Accounting Policies -        HTML     65K 
                Schedule of Reclassification (Details)                           
60: R45         Revenue -Revenues Disaggregated by Timing of        HTML     58K 
                Transfer of Goods or Services (Details)                          
61: R46         Revenue - Receivables and Contract Liabilities      HTML     42K 
                (Details)                                                        
62: R47         Revenue - Narrative (Details)                       HTML     64K 
63: R48         Revenue - Contract Liabilities from Contracts       HTML     47K 
                (Details)                                                        
64: R49         Revenue - Changes in Our Contract Liabilities from  HTML     36K 
                Contracts (Details)                                              
65: R50         Restructuring - Narrative (Details)                 HTML     38K 
66: R51         Restructuring - Schedule of Restructuring Charges   HTML     43K 
                (Details)                                                        
67: R52         Restructuring - Schedule of Severance and           HTML     38K 
                Personnel Liabilities (Details)                                  
68: R53         Cash Equivalents and Short-Term Investments         HTML     63K 
                (Details)                                                        
69: R54         Goodwill and Intangible Assets, net - Narrative     HTML     52K 
                (Details)                                                        
70: R55         Goodwill and Intangible Assets, net - Goodwill      HTML     42K 
                (Details)                                                        
71: R56         Goodwill and Intangible Assets, net - Intangible    HTML     65K 
                Assets and the Remaining Useful Lives (Details)                  
72: R57         Goodwill and Intangible Assets, net - Amortization  HTML     47K 
                Expense (Details)                                                
73: R58         Goodwill and Intangible Assets, net - Expected      HTML     43K 
                Amortization Expense for the Unamortized Acquired                
                Intangible Assets (Details)                                      
74: R59         Inventories (Details)                               HTML     38K 
75: R60         Accruals and other current liabilities - Schedule   HTML     45K 
                of Accrued Liabilities (Details)                                 
76: R61         Leases - Narrative (Details)                        HTML     76K 
77: R62         Leases - Operating Lease Costs (Details)            HTML     47K 
78: R63         Leases - Maturities of Lease Liabilities (Details)  HTML     85K 
79: R64         Leases - Remaining Lease terms and Discount Rates   HTML     40K 
                (Details)                                                        
80: R65         Leases - Supplemental Cash Flow Information         HTML     50K 
                (Details)                                                        
81: R66         Debt - Carrying Amount of Liability Component       HTML     55K 
                (Details)                                                        
82: R67         Debt - Interest Expense (Details)                   HTML     40K 
83: R68         Debt - Convertible Senior Notes (Details)           HTML     66K 
84: R69         Debt - Capped Call Transactions (Details)           HTML     49K 
85: R70         Debt - Notes Payable (Details)                      HTML     92K 
86: R71         Stock-based Compensation - Stock Option Plan -      HTML    135K 
                Narrative (Details)                                              
87: R72         Stock-based Compensation - Stock Option Plan -      HTML     70K 
                Summary of Stock Option (Details)                                
88: R73         Stock-based Compensation - Stock Option Plan -      HTML     64K 
                Summary of Restricted Stock Activity (Details)                   
89: R74         Stock-based Compensation - Stock Option Plan -      HTML     53K 
                Fair Value Assumptions (Details)                                 
90: R75         Stock-based Compensation - Stock Option Plan -      HTML     44K 
                Schedule of Stock-based Compensation Expense                     
                (Details)                                                        
91: R76         Stock-based Compensation - Unrecognized             HTML     47K 
                Compensation Cost (Details)                                      
92: R77         Stockholders' Equity (Details)                      HTML     69K 
93: R78         Stockholders? Equity and Stock-Based Compensation   HTML     42K 
                - Schedule of Common Stock Equivalents Excluded                  
                from the Calculation of Earnings per Share                       
                (Details)                                                        
94: R79         Fair Value Measurement - Schedule of Fair Value of  HTML     69K 
                Financial Instruments (Details)                                  
95: R80         Fair Value Measurement - Narrative (Details)        HTML     31K 
96: R81         Income Taxes -Income Taxes Provision (Details)      HTML     40K 
97: R82         Income Taxes - Effective Tax Rate Reconciliation    HTML     55K 
                (Details)                                                        
98: R83         Income Taxes - Deferred Tax Assets and Liabilities  HTML     66K 
                (Details)                                                        
99: R84         Income Taxes - Narrative (Details)                  HTML     53K 
100: R85         Income Taxes - Unrecognized Tax Benefits (Details)  HTML     36K  
101: R86         Commitments and Contingencies - Additional          HTML     54K  
                Information (Details)                                            
102: R87         Segment Information - Schedule of Reconciliation    HTML     43K  
                of Segment Revenue to Consolidated Revenue                       
                (Details)                                                        
103: R88         Segment Information - Schedule of Reconciliation    HTML     43K  
                of Segment Loss from Operations to Consolidated                  
                Loss from Operations (Details)                                   
104: R89         Subsequent Event (Details)                          HTML     37K  
105: R9999       Uncategorized Items - rvnc-20231231.htm             HTML     48K  
107: XML         IDEA XML File -- Filing Summary                      XML    193K  
110: XML         XBRL Instance -- rvnc-20231231_htm                   XML   2.44M  
106: EXCEL       IDEA Workbook of Financial Report Info              XLSX    215K  
12: EX-101.CAL  XBRL Calculations -- rvnc-20231231_cal               XML    322K 
13: EX-101.DEF  XBRL Definitions -- rvnc-20231231_def                XML    863K 
14: EX-101.LAB  XBRL Labels -- rvnc-20231231_lab                     XML   2.50M 
15: EX-101.PRE  XBRL Presentations -- rvnc-20231231_pre              XML   1.48M 
11: EX-101.SCH  XBRL Schema -- rvnc-20231231                         XSD    229K 
108: JSON        XBRL Instance as JSON Data -- MetaLinks              692±  1.01M  
109: ZIP         XBRL Zipped Folder -- 0001479290-24-000038-xbrl      Zip    911K  


‘EX-97.1’   —   Clawback Policy re: Recovery of Erroneously Awarded Compensation


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 C:   C: 
  Document  
Exhibit 97.1
Revance Therapeutics, Inc.
Incentive Compensation Recoupment Policy
1.Introduction
The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Revance Therapeutics, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this “Policy”) providing for the Company’s recoupment of Recoverable Incentive Compensation that is received by Covered Officers of the Company under certain circumstances. Certain capitalized terms used in this Policy have the meanings given to such terms in Section 3 below.
This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10D of the Exchange Act, Rule 10D-1 promulgated thereunder (“Rule 10D-1”) and Nasdaq Listing Rule 5608 (the “Listing Standards”).
2.Effective Date
This Policy shall apply to all Incentive Compensation that is received by a Covered Officer on or after October 2, 2023 (the “Effective Date”). Incentive Compensation is deemed “received” in the Company’s fiscal period in which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of such Incentive Compensation occurs after the end of that period.
3.Definitions
Accounting Restatement” means an accounting restatement that the Company is required to prepare due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.
Accounting Restatement Date” means the earlier to occur of (a) the date that the Board, a committee of the Board authorized to take such action, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement, or (b) the date that a court, regulator or other legally authorized body directs the Company to prepare an Accounting Restatement.
Administrator” means the Compensation Committee or, in the absence of such committee, the Board.
Code” means the U.S. Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder.
Covered Officer” means each current and former Executive Officer.
Exchange” means the Nasdaq Stock Market.
Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended.
Executive Officer” means a current or former officer of the Company as defined under Section 16 of the Exchange Act.  For the avoidance of doubt, this definition of “Executive Officer” is intended, and shall be interpreted, to reflect a current or former “executive officer,” as such term is defined in Section 10D and Rule 10D-1(d) of the Exchange Act and Nasdaq Listing Rule 5608.



Financial Reporting Measures” means measures that are determined and presented in accordance with the accounting principles used in preparing the Company’s financial statements, and any measures derived wholly or in part from such measures, including Company stock price and total stockholder return (“TSR”). A measure need not be presented in the Company’s financial statements or included in a filing with the SEC in order to be a Financial Reporting Measure.
Incentive Compensation” means any compensation that is granted, earned or vested based wholly or in part upon the attainment of a Financial Reporting Measure.
Lookback Period” means the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (resulting from a change in the Company’s fiscal year) within or immediately following those three completed fiscal years (except that a transition period of at least nine months shall count as a completed fiscal year). Notwithstanding the foregoing, the Lookback Period shall not include fiscal years completed prior to the Effective Date.
Recoverable Incentive Compensation” means Incentive Compensation received by a Covered Officer during the Lookback Period that exceeds the amount of Incentive Compensation that would have been received had such amount been determined based on the Accounting Restatement, computed without regard to any taxes paid (i.e., on a gross basis without regard to tax withholdings and other deductions). For any compensation plans or programs that take into account Incentive Compensation, the amount of Recoverable Incentive Compensation for purposes of this Policy shall include, without limitation, the amount contributed to any notional account based on Recoverable Incentive Compensation and any earnings to date on that notional amount. For any Incentive Compensation that is based on stock price or TSR, where the Recoverable Incentive Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement, the Administrator will determine the amount of Recoverable Incentive Compensation based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or TSR upon which the Incentive Compensation was received. The Company shall maintain documentation of the determination of that reasonable estimate and provide such documentation to the Exchange in accordance with the Listing Standards.
SEC” means the U.S. Securities and Exchange Commission.
4.Recoupment
(a)Applicability of Policy. This Policy applies to Incentive Compensation received by a Covered Officer (i) after beginning services as an Executive Officer, (ii) who served as an Executive Officer at any time during the performance period for such Incentive Compensation, (iii) while the Company had a class of securities listed on a national securities exchange or a national securities association, and (iv) during the Lookback Period.
(b)Recoupment Generally. Pursuant to the provisions of this Policy, if there is an Accounting Restatement, the Company must reasonably promptly recoup the full amount of the Recoverable Incentive Compensation, unless the conditions of one or more subsections of Section 4(c) of this Policy are met and the Compensation Committee, or, if such committee does not consist solely of independent directors, a majority of the independent directors serving on the Board, has made a determination that recoupment would be impracticable. Recoupment is required regardless of whether the Covered Officer engaged in any misconduct and regardless of fault, and the Company’s obligation to recoup Recoverable Incentive Compensation is not dependent on whether or when any restated financial statements are filed.
(c)Impracticability of Recovery. Recoupment may be determined to be impracticable if, and only if:
i.the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount of the applicable Recoverable Incentive Compensation; provided that, before concluding that it would be impracticable to recover any amount of Recoverable Incentive Compensation based on expense of enforcement, the Company shall make a reasonable attempt to recover such Recoverable Incentive Compensation, document such reasonable attempt(s) to
2



recover, and provide that documentation to the Exchange in accordance with the Listing Standards; or
ii.recoupment of the applicable Recoverable Incentive Compensation would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Code Section 401(a)(13) or Code Section 411(a) and regulations thereunder.
(d)Sources of Recoupment. To the extent permitted by applicable law, the Administrator shall, in its sole discretion, determine the timing and method for recouping Recoverable Incentive Compensation hereunder, provided that such recoupment is undertaken reasonably promptly. The Administrator may, in its discretion, seek recoupment from a Covered Officer from any of the following sources or a combination thereof, whether the applicable compensation was approved, awarded, granted, payable or paid to the Covered Officer prior to, on or after the Effective Date: (i) direct repayment of Recoverable Incentive Compensation previously paid to the Covered Officer; (ii) cancelling prior cash or equity-based awards (whether vested or unvested and whether paid or unpaid); (iii) cancelling or offsetting against any planned future cash or equity-based awards; (iv) forfeiture of deferred compensation, subject to compliance with Code Section 409A; and (v) any other method authorized by applicable law or contract. Subject to compliance with any applicable law, the Administrator may effectuate recoupment under this Policy from any amount otherwise payable to the Covered Officer, including amounts payable to such individual under any otherwise applicable Company plan or program, e.g., base salary, bonuses or commissions and compensation previously deferred by the Covered Officer. The Administrator need not utilize the same method of recovery for all Covered Officers or with respect to all types of Recoverable Incentive Compensation.
(e)No Indemnification of Covered Officers. Notwithstanding any indemnification agreement, applicable insurance policy or any other agreement or provision of the Company’s certificate of incorporation or bylaws to the contrary, no Covered Officer shall be entitled to indemnification or advancement of expenses in connection with any enforcement of this Policy by the Company, including paying or reimbursing such Covered Officer for insurance premiums to cover potential obligations to the Company under this Policy.
(f)Indemnification of Administrator. Any members of the Administrator, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy.
(g)No “Good Reason” for Covered Officers. Any action by the Company to recoup or any recoupment of Recoverable Incentive Compensation under this Policy from a Covered Officer shall not be deemed (i) “good reason” for resignation or to serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to such Covered Officer, or (ii) to constitute a breach of a contract or other arrangement to which such Covered Officer is party.
5.Administration
Except as specifically set forth herein, this Policy shall be administered by the Administrator. The Administrator shall have full and final authority to make any and all determinations required under this Policy. Any determination by the Administrator with respect to this Policy shall be final, conclusive and binding on all interested parties and need not be uniform with respect to each individual covered by this Policy. In carrying out the administration of this Policy, the Administrator is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee’s responsibility and authority. Subject to applicable law, the Administrator may authorize and empower any officer or employee of the Company to take any and all actions that the Administrator, in its sole discretion, deems necessary or appropriate to carry out the purpose and intent of this Policy (other than with respect to any recovery under this Policy involving such officer or employee).
3



6.Severability
If any provision of this Policy or the application of any such provision to a Covered Officer shall be adjudicated to be invalid, illegal or unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Policy, and the invalid, illegal or unenforceable provisions shall be deemed amended to the minimum extent necessary to render any such provision or application enforceable.
7.No Impairment of Other Remedies
Nothing contained in this Policy, and no recoupment or recovery as contemplated herein, shall limit any claims, damages or other legal remedies the Company or any of its affiliates may have against a Covered Officer arising out of or resulting from any actions or omissions by the Covered Officer. This Policy does not preclude the Company from taking any other action to enforce a Covered Officer’s obligations to the Company, including, without limitation, termination of employment and/or institution of civil proceedings. This Policy is in addition to the requirements of Section 304 of the Sarbanes-Oxley Act of 2002 (“SOX 304”) that are applicable to the Company’s Chief Executive Officer and Chief Financial Officer and to any other compensation recoupment policy and/or similar provisions in any employment, equity plan, equity award, or other individual agreement, to which the Company is a party or which the Company has adopted or may adopt and maintain from time to time; provided, however, that compensation recouped pursuant to this Policy shall not be duplicative of compensation recouped pursuant to SOX 304 or any such compensation recoupment policy and/or similar provisions in any such employment, equity plan, equity award, or other individual agreement except as may be required by law.
8.Amendment; Termination
The Administrator may amend, terminate or replace this Policy or any portion of this Policy at any time and from time to time in its sole discretion. The Administrator shall amend this Policy as it deems necessary to comply with applicable law or any Listing Standard.
9.Successors
This Policy shall be binding and enforceable against all Covered Officers and, to the extent required by Rule 10D-1 and/or the applicable Listing Standards, their beneficiaries, heirs, executors, administrators or other legal representatives.
10.    Required Filings
    The Company shall make any disclosures and filings with respect to this Policy that are required by law, including as required by the SEC.
*    *    *    *    *
4



Revance Therapeutics, Inc.
Incentive Compensation Recoupment Policy
Form of Executive Acknowledgment

I, the undersigned, agree and acknowledge that I am bound by, and subject to, the Revance Therapeutics, Inc. Incentive Compensation Recoupment Policy, as may be amended, restated, supplemented or otherwise modified from time to time (the “Policy”). In the event of any inconsistency between the Policy and the terms of any employment agreement, offer letter or other individual agreement with Revance Therapeutics, Inc. (the “Company”) to which I am a party, or the terms of any compensation plan, program or agreement, whether or not written, under which any compensation has been granted, awarded, earned or paid to me, the terms of the Policy shall govern.
In the event that the Administrator (as defined in the Policy) determines that any compensation granted, awarded, earned or paid to me must be forfeited or reimbursed to the Company pursuant to the Policy, I will promptly take any action necessary to effectuate such forfeiture and/or reimbursement. I further agree and acknowledge that I am not entitled to indemnification, and hereby waive any right to advancement of expenses, in connection with any enforcement of the Policy by the Company.

Agreed and Acknowledged:

    
Name:     
Title:     
Date:     




Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:2/28/248-K
For Period end:12/31/234
10/2/23
 List all Filings 


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/21/24  Revance Therapeutics, Inc.        DEF 14A     5/01/24   11:13M
 3/05/24  Revance Therapeutics, Inc.        424B5                  2:551K                                   Donnelley … Solutions/FA
 3/04/24  Revance Therapeutics, Inc.        424B5                  1:535K                                   Donnelley … Solutions/FA
 2/29/24  Revance Therapeutics, Inc.        S-8         2/29/24    4:123K


35 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/28/24  Revance Therapeutics, Inc.        8-K:1,2,5,9 2/23/24   13:618K
 2/13/24  Revance Therapeutics, Inc.        8-K:5,9     2/07/24   11:376K
11/14/23  Revance Therapeutics, Inc.        S-3ASR     11/14/23    7:846K                                   Donnelley … Solutions/FA
11/08/23  Revance Therapeutics, Inc.        10-Q        9/30/23   84:62M
 5/09/23  Revance Therapeutics, Inc.        10-Q        3/31/23   78:7.7M
 2/28/23  Revance Therapeutics, Inc.        10-K       12/31/22  109:14M
11/08/22  Revance Therapeutics, Inc.        10-Q        9/30/22   78:9.1M
 5/10/22  Revance Therapeutics, Inc.        10-Q        3/31/22   82:9M                                     Donnelley … Solutions/FA
 2/28/22  Revance Therapeutics, Inc.        S-8         2/28/22    5:197K
 2/28/22  Revance Therapeutics, Inc.        10-K       12/31/21  106:12M
12/22/21  Revance Therapeutics, Inc.        8-K:5,9    12/17/21   11:385K
11/09/21  Revance Therapeutics, Inc.        10-Q        9/30/21   81:8.4M
 8/05/21  Revance Therapeutics, Inc.        10-Q        6/30/21   79:8.5M
 5/10/21  Revance Therapeutics, Inc.        10-Q        3/31/21   76:6.7M
 5/07/21  Revance Therapeutics, Inc.        8-K:5,9     5/05/21   13:192K
 2/25/21  Revance Therapeutics, Inc.        10-K       12/31/20  109:12M
11/27/20  Revance Therapeutics, Inc.        S-3ASR     11/27/20    7:1.1M                                   Donnelley … Solutions/FA
11/20/20  Revance Therapeutics, Inc.        8-K:1,2,9  11/17/20   13:854K
11/09/20  Revance Therapeutics, Inc.        10-Q        9/30/20   83:8.3M
 8/06/20  Revance Therapeutics, Inc.        10-Q        6/30/20   64:7.2M
 7/24/20  Revance Therapeutics, Inc.        S-8         7/24/20    4:169K                                   Donnelley … Solutions/FA
 6/10/20  Revance Therapeutics, Inc.        S-4                   94:11M                                    Donnelley … Solutions/FA
 2/26/20  Revance Therapeutics, Inc.        10-K       12/31/19   85:11M
 2/14/20  Revance Therapeutics, Inc.        8-K:1,2,3,8 2/11/20   14:1.4M                                   Donnelley … Solutions/FA
11/04/19  Revance Therapeutics, Inc.        10-Q        9/30/19   60:5.7M
 2/28/19  Revance Therapeutics, Inc.        10-K       12/31/18   86:11M
 5/11/18  Revance Therapeutics, Inc.        8-K:1,5,9   5/10/18    2:261K
 5/09/18  Revance Therapeutics, Inc.        10-Q        3/31/18   54:4.5M
 5/09/17  Revance Therapeutics, Inc.        10-Q        3/31/17   63:4.4M
11/10/15  Revance Therapeutics, Inc.        10-Q        9/30/15   66:5.6M
 3/04/14  Revance Therapeutics, Inc.        8-K:1,9     2/26/14    2:52K                                    Donnelley … Solutions/FA
 2/11/14  Revance Therapeutics, Inc.        8-K:5,9     2/11/14    2:49K                                    Donnelley … Solutions/FA
 2/03/14  Revance Therapeutics, Inc.        S-1/A                  5:4.8M                                   Donnelley … Solutions/FA
 1/27/14  Revance Therapeutics, Inc.        S-1/A¶                22:5.2M                                   Donnelley … Solutions/FA
12/31/13  Revance Therapeutics, Inc.        S-1¶                  30:11M                                    Donnelley … Solutions/FA
Top
Filing Submission 0001479290-24-000038   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sun., Apr. 28, 10:03:00.3pm ET